Celularity Inc. Sells Series A Preferred Stock and Warrants in $2 Million Private Placement

Reuters10-28
<a href="https://laohu8.com/S/CELU">Celularity Inc.</a> Sells Series A Preferred Stock and Warrants in $2 Million Private Placement

Celularity Inc. has entered into a Securities Purchase Agreement with an institutional investor to issue and sell Series A Convertible Preferred Stock and accompanying warrants in a private placement of up to three tranches. Each tranche involves $2,000,000 in gross proceeds (90% of $2,222,222 stated value per tranche), for a total aggregate stated value of up to $6,666,667. The Series A Preferred Stock will be sold at 90% of the stated value, with a conversion floor price of $1.60 per share, subject to adjustments. The initial tranche closed on October 24, 2025, with additional tranches subject to certain conditions and at the investor's option. The company intends to use the net proceeds for working capital and general corporate purposes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celularity Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-019839), on October 28, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment